Research Funding
Research Project Seed Funding
ANZCHOG released a call for applications for one-off seed funding to support 12 month project/s that align with ANZCHOG's research objectives, to facilitate a program of research including clinical trials for childhood and adolescent blood diseases and cancer.
The closing date for applications was 30th January 2012. An assessment panel will review all applications with recommendations for funding submitted to the ANZCHOG Executive Council in March. Successful applicant/s will be notified by ANZCHOG in April.
Join a dynamic group of multidisciplinary professionals working in the fields of paediatric blood diseases and cancer.
ACCT trials may provide children with access to a greater range of therapies to treat their diseases.
Help us improve outcomes for children with cancer and blood diseases and their families.
View current ANZCHOG trial activity at The Australian Children's Cancer Trials Registry
Privacy Statement
Privacy Notice
We collect no personal information about you when you visit this website, unless you choose to provide this information to us. However, certain information about site visitors is automatically collected and stored.
Links to External Websites
Links from this website to other websites are for the convenience of the user. Such links do not constitute an official endorsement or approval of any website, product or service.
Disclaimer of Liability
Every effort is made to provide accurate and complete information. However, we cannot guarantee that there will be no errors. With respect to documents and information on this website, neither ANZCHOG, nor its employees and contractors make any warranty, expressed or implied, including the warranties of merchantability and fitness for a particular purpose with respect to documents available from this website. Additionally, ANZCHOG assumes no legal liability for the accuracy, completeness, or usefulness of any information, product, or process disclosed herein and do not represent that use of such information, product, or process would not infringe on privately owned rights.
